Clinical Trial Update: Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Pfizer's investigational crizotinib (PF-02341066) in ALK-positive non-small cell lung cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Neoplasms Malignant | Phase 1 | Status: TERMINATED | Results posted: 2025-01-23